Melanoma: Breaking the Mold in Immunotherapy What do we know about single agents vs. double agents in melanoma? Dr. Sapna Patel, an assistant professor in the Department of Melanoma Medical Oncology at MD Anderson Cancer Center ( talks about patients with BRAF and NRAS mutations and what therapies are showing remarkable responses with the use of combo agents. Dr. Patel talks about how treatments are impacting quality of life when compared to traditional chemotherapy and why clinical trial participation is key in making progress for one of our deadliest cancers today. Get email alerts | Subscribe on YouTube | Like on Facebook | Follow on Twitter |